4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 23rd Annual Global

Company Overview - 4D is a next-generation genetic medicines and gene therapy company utilizing directed evolution and Nobel Prize-winning technology to create customized vectors for targeted tissues, aiming for improved safety and lower production costs [1] Product Pipeline - The lead product, 4150, is an AAV-based gene therapy designed to express aflibercept for sustained treatment of wet AMD and diabetic eye disease, currently in two well-enrolling Phase III trials, indicating significant commercial potential [2] - Additionally, the company is developing a cystic fibrosis program featuring an inhaled agent that expresses the CFTR transgene [2]